UFA Creep: Time to Apply the Brake?
This article was originally published in RPM Report
Executive Summary
FDA’s user fee programs continue to proliferate. The new resources are great, but FDA and its stakeholders need to think carefully before going even further down this road.
You may also be interested in...
Biden’s FDA Commissioner Playbook: Build On COVID Innovations To Modernize Agency
Unintended silver lining of pandemic-generated innovation has brought the agency to an opportunistic fork in the road, and the commissioner choice will be consequential in determining the path forward.
Biden’s FDA Commissioner Playbook: Build On COVID Innovations To Modernize Agency
Unintended silver lining of pandemic-generated innovation has brought the agency to an opportunistic fork in the road, and the commissioner choice will be consequential in determining the path forward.
Scientific Wave Pushes CBER Into Brighter Light
What are US regulators doing to prepare for adequate review of the upcoming wave of gene therapy applications, and what other actions could CBER take to ensure it is able to facilitate the expected onslaught of breakthroughs in this field? Consultant Nancy Bradish Myers weighs in.